Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma

Patrick Terheyden*, Maja Ann Hofmann, M. Weininger, Eva B. Bröcker, Jürgen C. Becker

*Corresponding author for this work
18 Citations (Scopus)

Abstract

Purpose: The combination of the antiangiogenic antibody bevacizumab with standard chemotherapy has improved the prognosis in patients with metastastic colorectal cancer and other advanced cancers. The role of combined anti-VEGF and chemotherapy in metastastic melanoma is just starting to be elucidated. Methods: We tested this notion in three patients with advanced and therapy-refractory melanoma. Results: Interestingly, two patients achieved objective regressions after three courses of therapy; the third patient, albeit progressing demonstrated a pronounced liquid necrosis in bulky lymphnode metastasis. Conclusion: Further studies are warranted to scrutinise these impressive therapeutic effects on the combination of bevacizumab and chemotherapy in melanoma.

Original languageEnglish
JournalJournal of Cancer Research and Clinical Oncology
Volume133
Issue number11
Pages (from-to)897-901
Number of pages5
ISSN0171-5216
DOIs
Publication statusPublished - 11.2007

Fingerprint

Dive into the research topics of 'Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma'. Together they form a unique fingerprint.

Cite this